Keywords: genmab, regains, humax-tac, rights, danish, biotechnology, firm

Genmab regains HuMax-TAC rights

Article | 13 August 2007

Print This

Danish biotechnology firm Genmab AS has regained the HuMax-TAC antibody from Merck Serono after the latter's completion of a portfolio ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in